Señales en vivo de 268600.KQ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 mar 2023 @ 02:30):

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases...

Stats
Volumen de hoy	0.00
Volumen promedio	1.15M
Capitalización de mercado	244.94B
EPS	KRW0 ( 2024-03-21 )
Próxima fecha de ganancias	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW904.38 (13.54%)

Volumen Correlación

Largo: 0.03 (neutral)

Corto: -0.87 (strong negative)

Signal:(24.963) Be Aware. Possible trading coming up! (swing)

Cellivery Therapeutics, Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellivery Therapeutics, Correlación - Moneda/Commodity

-0.24
( neutral )

-0.39
( neutral )

0.08
( neutral )

-0.18
( neutral )

-0.21
( neutral )

Cellivery Therapeutics, Finanzas

Annual	2023
Ingresos:	KRW18.86B
Beneficio Bruto:	KRW-3.78B (-20.02 %)
EPS:	KRW-889.35

FY	2023
Ingresos:	KRW18.86B
Beneficio Bruto:	KRW-3.78B (-20.02 %)
EPS:	KRW-889.35

FY	2022
Ingresos:	KRW23.16B
Beneficio Bruto:	KRW-2.93B (-12.64 %)
EPS:	KRW-2 984.97

Financial Reports:

No articles found.

Cellivery Therapeutics,

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.